1. Home
  2. NAMS vs ASH Comparison

NAMS vs ASH Comparison

Compare NAMS & ASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • ASH
  • Stock Information
  • Founded
  • NAMS 2019
  • ASH 1924
  • Country
  • NAMS Netherlands
  • ASH United States
  • Employees
  • NAMS N/A
  • ASH N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • ASH Specialty Chemicals
  • Sector
  • NAMS Health Care
  • ASH Consumer Discretionary
  • Exchange
  • NAMS Nasdaq
  • ASH Nasdaq
  • Market Cap
  • NAMS 2.5B
  • ASH 2.4B
  • IPO Year
  • NAMS N/A
  • ASH N/A
  • Fundamental
  • Price
  • NAMS $19.85
  • ASH $53.68
  • Analyst Decision
  • NAMS Strong Buy
  • ASH Buy
  • Analyst Count
  • NAMS 8
  • ASH 5
  • Target Price
  • NAMS $42.88
  • ASH $70.75
  • AVG Volume (30 Days)
  • NAMS 1.0M
  • ASH 584.6K
  • Earning Date
  • NAMS 08-06-2025
  • ASH 08-05-2025
  • Dividend Yield
  • NAMS N/A
  • ASH 3.09%
  • EPS Growth
  • NAMS N/A
  • ASH N/A
  • EPS
  • NAMS N/A
  • ASH N/A
  • Revenue
  • NAMS $47,140,000.00
  • ASH $1,949,000,000.00
  • Revenue This Year
  • NAMS N/A
  • ASH N/A
  • Revenue Next Year
  • NAMS N/A
  • ASH $2.35
  • P/E Ratio
  • NAMS N/A
  • ASH N/A
  • Revenue Growth
  • NAMS 586.97
  • ASH N/A
  • 52 Week Low
  • NAMS $14.06
  • ASH $45.21
  • 52 Week High
  • NAMS $27.29
  • ASH $98.44
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 52.90
  • ASH 61.18
  • Support Level
  • NAMS $17.97
  • ASH $49.82
  • Resistance Level
  • NAMS $19.13
  • ASH $53.85
  • Average True Range (ATR)
  • NAMS 1.04
  • ASH 1.40
  • MACD
  • NAMS -0.03
  • ASH 0.43
  • Stochastic Oscillator
  • NAMS 35.63
  • ASH 96.96

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About ASH Ashland Inc.

Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.

Share on Social Networks: